click enter text
outlook januari issu monthli
report cover bull/bear case current controversi rel growth
prospect us eu global pharmaceut compani
overal sector view mix fundament decent total sharehold return
averag valuat in-lin histor level market-weight
under-perform ep growth decent intermedi term
long-term ep trajectori scari due biosimilar humira
astrazeneca outperform long-term ep growth almost peer
group averag seem like must stock
price-to-earnings group biggest io compani still valu
peer-perform solid prospect question whether
expect fulli anticip alreadi recent analyst meet compel
glaxosmithklin peer-perform plaudit chang thing good
eventu separ consum health much stori near-
term ep growth neg tsro dilut
merck outperform morph consensu buy
keytruda gardasil under-appreci big second driver stori
novarti outperform feel good catalyst-driven stori check
multipl box even though investor slowli turn posit valuat
peer-perform pipelin better still enough
drive out-performance ep next flattish
roch peer-perform on-going tug-of-war prospect
biosimilar exposur think latter keep money sidelin
sanofi peer-perform slowli return better growth catalyst-lit
arguabl downsid support low valuat
report limit sole use client wolf research pleas refer disclosur section locat end
www wolferesearch com/disclosur write us wolf research llc lexington avenu suit new york ny
analyst certif disclosur
page
tabl content
page
overal perspect global pharma sector exhibit temper view toward drug
industri overal industri fundament mix neither worst best time think
tailwind versu headwind latter moment posit side gener
product trend phase success rate among biopharmaceut compani turn
last sever year yet sever cover compani still individu late-stag pipelin
thin rel much spend annual rel larg size seem
overcapac mani compani chase smaller residu opportun
neg side drug price remain squar spotlight esp us variou propos aim
lower drug spend implement still also variou patent loss big drug across
industri lay ahead never end realli ebb flow vari compani drug compani
valuat reflect mani challeng alreadi group trade in-lin rel
total sharehold return basi outlook reason averag ep growth average ep compound-annual-growth-rate
averag dividend yield lead us sector rate market weight
exhibit overal perspect global pharma sector updat
page
major theme exhibit show think major theme sourc news
flow come year
exhibit major theme anticip
drug price varieti propos continu promulg histori suggest mani
like die vine scale back less oner propos
effect lobbi effort deep-pocket drug industri coupl congression inertia impact
reform measur gener requir act congress new law much shorter list chang
accomplish administr rule-mak process hh agenc
commerci side payer dynam quit differ public program side price govern
principl natur competit oppos govern regul misconcept
think privat payer simpli follow footstep govern despit privat commerci
payer nonetheless effect foster signific price competit sever instanc one risk
contempl next presidenti cycl democrat take white hous congress
substant polici chang could enact go presidenti elect talk
invari surfac among democrat hope singl payer system would bad healthcar
subsector biopharmaceut
partial list potenti case actual chang date includ
page
medicar part recent propos address six protect class drug
insul aggress payer action new rule help pave way price competit see
report remov protect drug class statu come one chang
medicar part began allow medicar advantag plan limit manag part drug
close broadli bipartisan support shift away tradit buy bill
framework arguabl skew physician incent physician may ultim taken
mix allow payer better manag type drug recent propos benchmark price
basket intern price invari lower us price like becom realiti
medicaid state medicaid program seek waiver grant author use
tradit formulari manag tool like formulari tri lower drug spend often lower
profit channel biopharmaceut compani medicaid spend drug roughli
state-level initi lack feder action individu state increasingli take
matter hand come initi tackl drug price exampl california
drug price transpar bill requir justif drug price increas certain level
away rebat heighten attent practic rebat
discount pharmaceut compani make payer return better market access drug
compani quick point insur act unnecessari middleman
skim much revenu stream without pass along save insur
constitu may propos pass rebat consum point sale
seem unlik rebat elimin altogeth
push gener includ biosimilar free-market solut problem one
champion approach fda commission scott gottlieb free-market approach
idea foster price competit make sure gener approv bottleneck clear
part roadblock greater biosimilar usag evalu view reform-lit
someth industri would gener support lesser evil
exhibit use think impact us reform could global pharmaceut
compani put us drug spend relat global drug spend show split payer
channel us global drug spend us repres total us
simplist carv two main bucket commerci public program take-away
impact small chang us program get dilut given global revenu mix mnc
page
exhibit summar compani exposur us payer channel vari meaning
exhibit payer exposur us drug busi compani
page
companycommercialpart bpart info provid largest part drug keytruda largest part drug add info provid -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- novn vs peer average vs peer average vs peer vs total compani sale expos medicar vast major part add info provid -- -- -- -- -- -- -- -- -- approx compani irblack wr best guess base compani disclosur azn commerci includ non-contract sale gpo/ltc sale
valuat perform exhibit show forward price-to-earnings multipl coverag univers rel
last rel price perform coverag univers vs
exhibit valuat perform rel
exhibit show rel revenu ep growth rate cover compani index three
differ time period shown
view accur
page
exhibit compar revenu ep growth rate
page
view view view reveneu growth ep growth ep growth reveneu growth ep growth revenu growth
exhibit base revenu analysi look growth profil cover compani collect
product market today exclud futur pipelin drug includ revenu divis
consum health anim health diagnost across two differ period intent
exhibit show longer stretch time compani biggest futur loss
contend usual due patent expir drug compani long-rang plan take
consider think much spend put behind potenti target
key point make
view differ view least compani
smaller pure play compani tend fastest growth
pure play compani also tend volatil base revenu
compani fortun enough posit base revenu growth least next
sever year patent expir cycl
exhibit base revenu growth
exhibit comp sheet cover stock certain larg cap therapeut name also shown
refer
page
factset wolf research price
page
azn w/o europ healthcar compani comparison cover pharma target multipl
rate price target summar exhibit
azn novn rate outperform like azn best novn
one notch lower lower long-term ep growth rel three
gsk san rate peer-perform gsk look intrigu
us chang view sinc re-launch oct
rate under-perform
exhibit wr summari rate price target
factset wolf research price
page
compani report factset wolf research price
page
wolf bullet-point view
investor sentiment bifurc viewpoint love hate
pipelin prowess abil best phase pipelin optic look full
mani compound natur
binari event risk noth discret addit pipelin misstep rova-t failur would
hurt given imper lessen depend humira question anticip whether
pursu larger almost seem inevit question time
near-term outlook growth near-term decent question mark given recently-revis
steeper sale eros ex-u humira
long-term outlook good base model
valuat cheapest price-to-earnings lag peer summer rotat pharma
net remain cautiou due uncertainti impact humira
biosimilar admittedli consensu concern least among worri
singl product concentr risk degre vastli exce compani
cover product unfortun tail end life cycl odd name
competit growth next year substanti pressur earn begin
think margin de-lever under-model eu biosimilar humira launch sinc
octob belief new money sit one engag larger distinct
possibl otherwis get hand meaning new product perhap stori get
press report claim offer discount nordic countri tender respons eu
humira biosimilar launch rais concern could set worrisom preced
market
announc posit result studi show venetoclax combo obinutuzumab
significantli improv compar soc obinutuzumab plu chlorambucil cll patient
report financi result beat ep guidanc rais dividend increas
bigger news howev neg revis previou ex-u humira biosimilar eros
assumpt expect ex-u eros y/i eros
lower taper beyond detail see full postview ep
rais ex-u biosimilar eros assumpt goe deep end
announc humira biosimilar agreement time momenta similar patent licens
structur previou samsung bioepi freseniu kabi sandoz momenta allow
page
enter us novemb month first allow enter eu upon
approv ema also settl boehring ingelheim remain challeng
receiv acceler fda approv venclexta combo hypomethyl agent hma
low-dos cytarabin ldac aml origin pdufa date dec
uk nation health servic nh issu press releas suggest reduct price
follow biosimilar entri nh describ reduct biggest nh histori singl drug
halt enrol taho studi evalu rova-t sclc base shorter
os observ rova-t arm trial continu
file upadacitinib jak inhibitor us/eu treatment adult moder sever ra
base select trial approv expect end earli
import upcom event next
read-out pancreat resolv cll combo w/ rituximab allianc
approv ibrutinib obinutuzumab combo cll/sll
competitor event late azn acalabrutinib vs ibrutinib r/r cll elev cll
read-out combo w/ bortezomib r/r mm bellini
regulatori approv psoriasi
upadacitinib jak anticip approv ra end base file announc
depatux-m egfr studi glioblastoma gbm concomit radiotherapi
temozolomid tmz readout
page
biosimilar patent litig septemb court rule expect earli outcom favor
sandoz erelzi could launch earlier expect would sudden/unexpect competit pressur
us humira off-the-radar risk
 like hunt larger given size humira hole eventu fill
uncertainti time doesnt near-term think could make sens would creat
oncolog powerhous meaning blunt us humira eros
humira parti yet even eu biosimilar launch global brand continu
grow margin high estim global oper margin also expir
cabilli patent lessen royalti pay serv partial off-set eu eros us
biosimilar dont launch like long way away
phase pipelin full under-valued hand de-risk late-stag candid
street significantli manag expect jak leverag exist
humira relationship bundl jak forc favor payer access
b-cell tumor franchis imbruvica/venclexta great outlook imbruvica great
venclexta come onto scene interest product high margin product
stock cheap lowest-in-the-group price-to-earnings multipl alreadi anticip humira biosimilar concern
stock under-valu taken context ep growth deliv near- mid-
term manag long-term guidanc right stock realli under-valu
buy solut stock would like react well unless equity-bas
transact larg deal would like could creat arb-rel pressur
humira fund compani biosimilar hurt expect stori killer
manag recent downward revis ex-u eros guidanc show manag may
difficulti predict futur humira trajectori eu humira profit higher investor expect
view biosimilar uncertainti acut chronic psycholog overhang
could chang rebat environ us impact humira durabl humira abl
thwart competit partli high level rebat pay payer rebat paradigm
chang discuss washington take away one key advantag
page
phase pipelin numer full mostli me-too product rova-t one compound
novel seem dead jak class class minim differenti categori
compet face ever-increas brand generic/biosimilar competit
imbruvica import off-set humira could potenti unseat follow-on btk inhibitor
oncolog product clearli better data quickli displac older product azn head head
data late wolf comment later-gener btk inhibitor realli materi better data
lack moment
outlook biggest market product collect total revenu
humira variou autoimmun disord world biggest drug reliabl
consist sourc growth face uncertainti biosimilar enter pictur
mavyret hcv abbv new improv hcv offer viekira rapid uptak
stun howev global sale may alreadi peak gaug rate declin
imbruvica variou b-cell malign lead asset pcyc acquisit big
product big growth expect must continu monitor gener btk possibl threat
creon pancreat enzym replac therapi legaci specialti drug patent
protect gener yet unclear show
lupron variou hormone-rel disord treat endometriosi uterin fibroid
prostat cancer central precoci puberti face partial intra-portfolio cannib recently-
pipelin asset gener later-stag candid visibl higher includ
upadacitinib jak oral select inhibitor file ra psoriat arthriti crohn
diseas ulcer coliti atop dermat manag promis differenti jak profil vs pfe
xeljanz olumi assur dvt/pe profil issu one reason got
trip asset clearli within abbv domain expertis manag guid
ww sale model way best-in-class efficaci third
entrant jak class serv indic heavi brand increasingli gener competit
risankizumab file psoriasi clinic profil compar jnj tremfya guselkumab offer
conveni dose schedul vs anoth import late-stag asset fill humira
footstep manag guid ww sale model way entrant
class serv indic heavi brand increasingli gener competit
page
imbruvica btk indic expans true pipelin product per se approv cll mcl mzl
waldenstrom macroglobulinemia gvhd push earlier line treatment new tumor
type follicular lymphoma activ cll less activ outsid cll alreadi multi-billion-dollar
blockbust product good growth ahead far lead vs btk big downsid risk
gener btk azn acalabrutinib abl demonstr superior
consensu expect econom share
venclexta indic expans true pipelin product per se approv r/r cll
without del expans earlier line cll treatment tumor type aml mm
mcl partli live imbruvica shadow novel highli activ drug kol academ
center embrac drug fear pervad within commun set around drug safeti profil
low risk tumor lysi syndrom probabl deserv attent receiv today great opportun
broadli combin imbruvica one two punch econom share roch
rova-t stemcentrx acquisit treatment sclc triniti
sclc fail impress march irc orr irc dor month cross-trial
comparison basi look meaning better chemo close window acceler
file taho halt sclc base recommend idmc meru mainten
sclc continu expect re-bas even success upcom earlier line
treatment compet
depatuxizumab mafodotin egfr product seem get much
attent pediatr gbm w/egfr amplif primari read began
page
valuat lowest group price-to-earnings full comp sheet see exhibit trade price-to-earnings
multipl ep ep ep use
target price-to-earnings multipl appli ep arriv year end price target target
multipl roughli in-lin current price-to-earnings multipl level use price target multipl across cover
compani rang
abbv incom statement revenu forecast balanc sheet/cash flow statement see appendix
financi statement end report
page
astrazeneca azn op pt long-term ep growth group averag plu
pipelin big china presenc take-out potenti
compani report factset wolf research price
page
wolf bullet-point view azn
investor sentiment gener attract azn futur growth prospect understand avers
extern feel like cook book
pipelin prowess thin higher-risk compound bace anifrolumab
occur still variou opportun phase commonli view major pipelin stori
histor great compani
binari event risk volatil roxadustat cardiovascular safeti data earli
near-term outlook decent usher revenu ep growth hope
valuat expens near-term ep price-to-earnings normal out-year given superior growth prospect
net continu like azn best long-term grower group turn around
margin expans stori new growth come already-approv product
mean azn heavili depend futur pipelin traction unpredict said
azn still late-stag pipelin opportun ahead overal investor expect
overli high like two aspect azn footprint china vastli greater
compani could sourc long-term competit advantag potenti azn
could one day take-out target one smaller compani sector recal pfe attempt
report posit top-line result trial studi lynparza mainten therapi
newly-diagnos advanc brca-mut ovarian cancer subsequ submiss accept
fda prioriti review pdufa expect
report solid quarter in-lin revenu ep guidanc maintain
 driven base also pipelin
announc final result phase mystic trial imfinzi monotherapi
imfinzi tremelimumab nsclc meet primari endpoint overal surviv patient whose
tumor express howev clear posit trend monotherapi arm
statist under-pow stock shrug result
announc failur phase eagl trial scchn neither imfinzi monotherapi
imfinzi tremelimumab combo met primari endpoint improv os
page
announc approv roxadustat china treatment patient anemia caus
chronic kidney diseas ckd dialysi first approv product separ
azn announc posit top-line result phase olympu rocki trial
treatment anemia patient ckd non-dialysis- dialysis-depend
announc fda approv lynparza mainten treatment brca-mut ovarian
import upcom event next
nsclc trialsneptun poseidon investor expect low
especi recent failur mystic os mean upsid downsid realli
poseidon also durva chemo chemo combo arm often over-look
addit lung cancer trial tumor type includ scchn bladder
cancer role combo azn futur set tbd
ovarian bevacizumab combo regardless brca statu hrrmt mcrpc profound
roxadustat anemia efficaci trial read await analysi cv safeti pool
analysi differ trial earli regulatori submiss investor expect mix
partli checker histori compound anemia/epo/esa space also
commerci dynam dialysi market entrench competit pre-dialysi treatment market doesnt
calquenc cancer head-to-head trial elev abbv imbruvica r/r cll
poor-risk cll late nccn alreadi recommend r/r cll clear us physician use
alreadi indic investor cautious optimist
anifrolumab lupu read-out second trial lupu soon possibl updat earn
expect natur low first trial fail earlier year
noth materi think
page
best lt ep growth big pharma inflect point financi importantli
growth come newer base approv product word azn futur growth
heavili depend futur pipelin success difficult call
margin expans stori azn cost structur heavili out-of-whack follow period heavi patent
expiri burden expiri move background organ growth return due
variou import new product launch tagrisso farxiga imfinzi lynparza lead natur
margin expans substanti
heavi exposur oncolog one hottest diseas area azn exposur oncolog
nearli grow place concentr diseas area
second high-growth high-margin market segment cover compani
want increas exposur
heavi exposur china import em azn exposur china nearli
total product sale grow healthi double-digit level exposur peer group azn
say margin china similar margin europ despit sell price china
much lower exampl tagrisso price china lower us azn recent
struck deal gain coverag china nrdl
take-out potenti tri seem move big strateg mistak
get deal close view compani could still come knock howev
extern artifici ep boost stock even expens alreadi appear
practic sourc controversi sinc began manag wont say
time-frame ramp acknowledg peak ramp creat
tough comp given high profit dollar
margin expans alreadi bake doesnt deliv wolf comment admittedli margin
expans big pharma tend elus commonplac
mix qualiti pipelin failur could impact investor percept azn rebuild
pipelin stori alreadi bace anifrolumab met demis although compound
fail share price move much furthermor azn big bet io durvalumab tremelimumab
io/io combin seem increasingli unlik ever bear fruit
symbicort greater risk consensu model previous said stay assum
su carri gener timelin consensu contrast doesnt seem model substitut
gener ever even true gener show gener advair gsk us pressur symbicort
wolf comment us symbicort gener annual sale small
page
earlier-than-expect competit pacif small trial hoosier oncolog
group popul patient resembl pacif could theoret lead
nccn compendia list wolf comment would like recommend weak
one therefor enough make meaning differ
ceo pascal soriot leav press report look previous join teva
board initi formal search replac yet pascal assur go
outlook biggest market product collect total revenu
symbicort asthma/copd tail end life cycl face addit indirect pressur
gener advair symbicort gener show model best guess
farxiga diabet one three franchis gener expect mid-
competit strong jardianc invokana recent declar cvot trial result
give small boost weaker lli empa
tagrisso cancer earli life cycl expect major futur growth driver
azn especi import asian market like japan china synerg well azn market-
lead china penetr small molecul drug royalti burden littl come competit
crestor hypercholesterolemia lost patent protect long ago sale still prop
emerg market enough still top drug azn
nexium gastroesophag reflux anoth post-lo drug sustain ex-u ex-eu
revenu recent announc outlicens eu right grunenth complet
anoth big sourc extern revenu
pipelin asset gener later-stag candid visibl higher includ
tagrisso anti-egfr tki mtegfr nsclc indic expans true pipelin drug per se
await matur os data flaura like also run adjuv trial adaura
report investor given one much thought yet evid anti-egfr
tki yield benefit set less clear
lynparza parp variou cancer indic expans true pipelin drug per se lynparza
co-develop merck alreadi approv ovarian cancer mani studi
set on-going predict good efficaci variou cancer brca mutat express
infrequ azn/mrk tri expand tumor brca limit combin
therapi exist medicin well pipelin product azn dna damag repair
page
ddr portfolio includ agent inhibitor atm inhibitor
azn claim commerci futur compound underestim
roxadustat oral hif-ph anemia azn us/china right complex three-way partnership
astella eu origin commerci futur partli depend whether show better
cardiovascular safeti demonstr pool result trial like olympu non-dialysi ckd
mace non-inferior vs placebo rocki dialysi ckd mace superior vs epogen
tezepelumab anti-tslp mab asthma novel biolog block master regul asthma
inflamm pathway recd breakthrough therapi design data asthma suggest efficaci
regardless eo level holi grail excit mechan enter potenti crowd market
share econom trial run pathfind navig result
calquenc acalabrutinib btki mcl cll indic expans true pipelin drug per se
acerta acquisit go market leader imbruvica virtual
monopoli btki space azn hope differenti safeti three phase trial cll
earlier stage trial heme tumor
imfinzi tremelimumab main combo strategi azn io portfolio mystic os nsclc
recent fail os readout least mono durva trend in-lin pdx
deliv arm under-pow howev unclear imfinzi treme ever approv
pearl neptun poseidon studi data indic scchn bladder sclc
deck would enter io experienc market
anifrolumab failur first tulip trial sle lower expect tulip data expect
neg data second trial could last nail coffin
growth profil trough solid grower
page
valuat highest group full comp sheet see exhibit azn trade price-to-earnings multipl
ep ep ep use target price-to-earnings multipl
appli ep arriv year end price target target multipl
repres modest expans current price-to-earnings multipl level assum ep come level
expect azn continu execut expect multipl expans partli
pauciti high growth name sector use price target multipl across cover
compani rang
azn incom statement revenu forecast balanc sheet/cash flow statement see appendix
financi statement end report
page
bristol-my squibb op pt even buy rate wade
controversi like upsid vs downsid
compani report factset wolf research price
page
wolf bullet-point view
investor sentiment given recent spate neg news io grow sens cant seem
get right sell capitul fewest buy rate group
pipelin prowess pipelin thin interest point nktr-
offer upsid downsid
binari event risk ye relat io news flow competitor never-end sourc
news seem
near-term outlook financi result solid shape next sever quarter investor
expect opdivo overal clearli moder opdivo yervoy like continu
disappoint lung
long-term outlook growth clearli correl trajectori opdivo beyond uncertainti
point big debat current model show decent lt ep growth assum opdivo
hold reason well go forward
valuat contract significantli price-to-earnings multipl best
net clearli controversi rate volatil
stock tie mishap immuno-oncolog space lost major lead
merck space continu controversi long-term trajectori opdivo
investor expect moder uncertainti price plausibl scenario opdivo
continu remain one two market lead therapi lung think opdivo yervoy
continu disappoint chemo combo work would relief part data
one import long-term sourc upsid option anti-pdx therapi work earlier
stage adjuv cancer set data come time-frame still far away like
azn also offer degre take-out potenti thesi biopharmaceut
compani want gain broad-platform realist get one way
target would accomplish yet take-out premium share price
report result in-lin revenu handili beat ep guidanc rais
detail see full postview strong cheap stock
announc neg top-line result opdivo yervoy extensive-stag
sclc second failur sclc opdivo monotherapi fail
octob could potenti put jeopardi opdivo acceler approv sclc
certain perspect see failur show
therapi lag lung cancer
page
import upcom event gener next
chemo cycl earli assum
base regimen like fail lung
 bmi balanc sheet net cash posit consist said prepar remark
busi develop remain top prioriti yet done small deal last year
still among fastest grower pharma even opdivo setback lung opdivo eliqui
primari driver
still formid player io lung combin continu look iffi
opdivo use combin chemotherapi yield posit result even consensu number
trim still one two main pdx player larg shut competitor
three long-term sourc io categori upsid would benefit two market leader
disproportion three long-term sourc import upsid io categori
mind adjuv opportun anti-pdx therapi get use earlier-stag diseas
would translat even bigger difficult quantifi market opportun potenti under-
model ex-u anti-pdx opportun base histor preced meaning cancer drug
usual sell outsid us us consensu current model revers
industri final succeed find synergist agent combin anti-pdx therapi make
greater proport patient respons therapi admittedli lot disappoint
date front
valuat come bmi low price-to-earnings multipl best
take-out candid one smaller revenu base would easier digest bring
acquir one two market-lead
page
uncertain opdivo trajectori could go ex-growth period sale transit lung
indic given renal data along bmi setback sclc manag
guid continu opdivo growth given guidanc beyond
tmb becom real push tumor mutat burden import new
biomark io howev data tmb look good os seem elus
thin phase pipelin despit spend mean stori mostli center opdivo
time bring sharper focu futur like eliqui
disproportion sensit potenti us healthcar reform due product mix among
highest exposur coverag program like medicare/medicaid meaning reform
program ep could disproportion hit
outlook biggest market product collect total revenu
opdivo cancer formerli market-lead recent surpass keytruda
maintain growth may depend indic outsid nsclc off-pat
time-frame
eliqui stroke/dvt market-lead oral anti-coagul split growth
continu linearli displac warfarin target undiagnos untreat popul off-pat
yervoy cancer approv azn may never see light day
mayb smart divest growth depend expans opdivo yervoy combo
indic lower dose shown accept toxic still deliv efficaci
sprycel leukemia matur product expect enter ex-growth phase near-term
gener possibl enter ex-u soon indirect pressur gener gleevec/imantinib us
orencia autoimmun diseas matur product still grow crowd arthriti
market clear biosimilar competit sight
pipelin asset gener later-stag candid visibl higher includ
page
opdivo yervoy indic expans true pipelin drug per se opdivo
approv mel nsclc rcc hodgkin scchn msi-h bladder variou trial
on-going host tumor type term combin approv mel
rcc studi tumor type well import nsclc
inh recent start psoriasi result data decent
category-lead key oral therapi versu newer approv agent
inject crowd space earlier phase evalu underway includ lupu ibd
program evalu tumor phase trial combin opdivo start recent melanoma
data phase data shook investor confid asset
relatlimab phase trial combin opdivo mel data phase data
shown signal terribl strong one view
variou earlier-stag i/o drug human studi anti-kir anti-gitr other difficult
ascrib valu mani earlier stage asset given human data publish
date gener slow progress across industri next gen io agent either monotherapi
combin seem advanc
growth profil decent toggl opdivo trajectori uncertain
page
valuat current price-to-earnings among lowest full comp sheet see exhibit trade price-to-earnings multipl
ep ep ep use target price-to-earnings
multipl appli ep arriv year end price target target multipl
repres expans current price-to-earnings multipl level believ oversold territori despit
uncertainti opdivo assum posit chemo combo data come bmi
multipl move higher use price target multipl across cover compani rang
bmi incom statement revenu forecast balanc sheet/cash flow statement see appendix
financi statement end report
page
pp pt execut well expect high
compani report factset wolf research price
page
wolf bullet-point view
pipelin prowess histor one better organ late-stag pipelin
interest opportun promis tirzepatid
near-term outlook recent gave guidanc healthi well expect
long-term outlook solid one better long-term growth rate
valuat valuat second highest group azn
net come long way last sever year upgrad stock
heavili favor pendulum clearli swung stock consensu
buy re-launch wolf late peer-perform rate feel
risk reward evenli balanc strong run throughout year howev back
guidanc given decemb analyst day long-term outlook admittedli seem better
initi model leav well-posit compani still substanti exposur diabet
revenu categori seem well posit rel peer also categori
price competit meaning
announc posit top-line result rewind cvot trial trulic demonstr
superior reduct mace event
report result in-lin revenu beat ep guidanc rais
detail see full postview rais larg quiet
quarter sell-off high expect
announc nda submiss lasmiditan treatment acut migrain fda decis
expect
announc guidanc held analyst day guidanc appreci
our/consensu posit meet overal increment new disclosur in-lin product
 program detail see global pharmaceut guidanc recap model
import upcom event next
page
trulic full rewind cv data present june ada seem excit
tanezumab ngf oa trial studi read-out earli long-term oa safeti trial studi
chronic lower back pain tango need file
tirzepatid releas dose titrat data ada
lasmiditan readout posit acut migrain recent submit fda mean
pegilodecakin trial nsclc pegliodecakin keytruda readout
trial nsclc pegliodecakin opdivo readout
noth mention
collect growth driver approv still pipelin small revenu base
lli compar smaller revenu base vs peer compani often almost
give compani greater earn leverag
margin expans stori deliv commit long-term spend target first
given intim margin expans go forward
tirzepatid give long-term protect diabet franchis given
could multi-year lead competitor blood sugar control weight loss data category-lead
alzheim provid potenti major long-term option eventu find success
would truli transform would send share straight noth stock
fact investor bear burden ep necessari spend fund program
although assur us spend high mani believ
price perfect current level expens rel growth like deliv unless
margin expans occur faster rate expect
lli diabet exposur liabil two differ front
page
lli current overal exposur diabet high total compani sale even
elanco divest area fierc price competit outcom
payer negoti sometim come unpleas surpris next year guidanc
given decemb lli case
trulic face competit novonordisk oral semaglutid could launch possibl
categori growth high enough support multipl product trulic could still
feel impact depend sema clinic profil price gip/glp doesnt launch
compani guidanc may protect franchis anytim soon
tanezumab set disappoint class checker histori lly/pf seem semi-
cautiou describ safeti hurdl yet cross even get approv commerci
case may prove elus partli opioid crisi someth seem exist us
tirzepatid expect super high base singl phase trial drug hit target
gip other fail long-term safeti profil still need clearli defin
outlook biggest market product collect total revenu
trulic diabet one two market-lead franchis strong growth prospect
uncertain degre risk oral
humalog diabet tail end life-cycl begin face biosimilar us/eu
forteo osteoporosi tail end life-cycl possibl face first biosimilar competit
alimta cancer matur product grow much even increas usag
conjunct pdx eu alreadi face gener us gener
ciali erectil dysfunct yet anoth product tail end life cycl start face
gener current year
pipelin asset gener later-stag candid visibl higher includ
dual incretin agonist diabet suddenli high expect
stem placebo- active-compar random control data better blood
sugar control better weight loss toler moder wors say dose titrat
reduc investor keep mind howev singl phase dose-rang trial
wont stop howev launch phase trial
page
tanezumab ngf novel non-opioid mechan sever pain partial clinic hold lift pursu
indic osteoarthr chronic lower back pain first studi posit still need read-
out anoth oa trial studi chronic lower back pain studi tango better defin
rpoa safeti signal
lasmiditan acut migrain non-triptan oral therapi avoid vasoconstrict seem
caus dizzi paresthesia interest oral therapi acut attack
complement cgrp antagonist
pegilodecakin pegyl came armo acquisit
drug alreadi variou phase trial purportedli singl agent activ
first phase read sequoia pancreat cancer pegliodecakin folfox readout
alzheim past failur solanezumab lanabecestat numer compani keep
investor expect disease-modifi drug alzheim low scienc slowli
progress lli focu a-beta specif antibodi antibodi anti-tau antibodi
combo broad ad platform
growth profil steadi growth continu margin expans
page
valuat second highest price-to-earnings multipl group full comp sheet see exhibit trade
price-to-earnings multipl ep ep ep use
target price-to-earnings multipl appli ep arriv year end price target
target multipl roughli in-lin current price-to-earnings multipl level use price target multipl across
cover compani rang
lli incom statement revenu forecast balanc sheet/cash flow statement see appendix financi
statement end report
page
glaxosmithklin gsk pp pt definit shake thing upsid case still
compani report factset wolf research price
page
wolf bullet-point view gsk
investor sentiment mix point view
pipelin prowess thinner side term late-stag product raw abil
total devoid bcma gsk promis turn around new leadership
binari event risk noth call materi
near-term outlook stock volatil back tsro acquisit caus sell-off
consum jv format led share price rebound seem like quieter partli
much way catalyst ep growth neg due tsro dilut
trough hiv uncertainti remain due competit script trend need monitor
long-term outlook steadier ep growth trajectori yet ep still ep
valuat price-to-earnings lower end peer group averag
net current level gsk face limit downsid risk pipelin thin
total devoid growth profil modest compani activ tri chang thing
win plaudit old new approach recent exampl includ commit
split newly-form consum health far away effect meaning chang
big organ like gsk easi histori show often fall flat patient valu investor
gsk may make sens especi dividend yield everyon els stori doesnt yet
feel ripe enough hiv competit threat possibl chang payer dynam need
report posit top-line result flair studi inject cabotegravir rilpivirin
treatment hiv pool data flair atla form basi regulatori submiss
report result in-lin revenu beat ep guidanc rais
detail see gsk full postview rais in-lin revenu
propos chang six protect drug class relev medicar part gsk
exposur hiv asset anticip may occur see remov protect drug class
statu come propos includ rule could limit price increas see one chang
host final pipelin unplug confer call gsk detail see
 gsk highlight pipelin unplug call execut
page
announc divest horlick consum healthcar nutrit brand unilev
deal expect complet end
announc acquisit tesaro fund partli consum asset sale guid
ep dilut next year share sink due ep dilut question around valu lead asset
announc import agreement combin compani consum health
busi new jv major own gsk gsk commit separ entiti
stand-alon compani within year deal closur suggest detail see global
 gsk perspect new consum jv form
import upcom event next
bcma antibodi drug conjug pivot trial readout triple-refractori
dolutegravir/lamivudin hiv recent file prioriti review voucher fda decis
cabotegravir hiv phase trial cabotegravir rilpivirin expect readout
gener advair launch presum get approv substitut gener sometim
come month sandoz hikma teva approv farther gsk may launch author gener
captur valu gener channel gener final launch clear event
gsk happen
tsempano safeti updat dolutegravir small trial africa tsempano studi show
neural tube defect pregnant women dtg led label warn us geographi
receiv littl attent follow analysi report addit case due mar/april
time-frame radar risk investor
bull case gsk risk upsid
sum-of-the-part basi gsk attract larger exposur consum health xx
sale follow jv consumm appli compar price-to-earnings busi use
consum compani comp show impli price-to-earnings multipl gsk pharma busi low
page
ceo chang thing made lot outsid hire think luke miel barron kevin sin iain
mackay done one acquisit tsro commit eventu spin consum health
creat hope trade demonstr proactiv manag team noth els sharehold
dividend yield higher group averag
valuat low toward low end peer group rang rarer gsk
c-suit execut without pharma background newer ceo emma walmsley light
pharma/vaccin experi clearli core profit driver gsk new cfo iain mackay likewis
pharma background join hsbc
turn around tall order especi new head live far away
gsk respect new head resid sf bay area long way stevenag uk
pennsylvania us gsk late-stag pipelin thinner side question remain
commerci opportun lead asset anti-bcma
balanc sheet constrain gsk balance-sheet constrain lock high dividend
pay-out abil way bring new franchis new asset limit esp post
variou threat hiv/aid franchis total sale key growth driver
threat includ gild biktarvi bictegravir taf direct competit gsk tivicay/triumeq
take share gsk defens so-cal two-drug regimen weak
one may fear resist us payer dynam may chang chang
protect drug class statu one chang cap price increas tsempano studi
follow-up clearli answer question neural-tub defect off-the-radar risk downsid
could competit disadvantag dolutegravir
suppli limit shingrix gsk say curtail growth new suppli open difficult
know analyst model correctli
outlook biggest market product collect gbp total
advair asthma/copd declin product cusp first us gener entri
acceler declin even faster
relvar/breo asthma/copd slow grower near mid-term crowd respiratori
page
triumeq growth slow near term gilead biktarvi continu pose
tivicay remain decent grower near mid-term continu face risk
gilead biktarvi
shingrix singl vaccin new vaccin well whose efficaci blow
competit merck zostavax away suppli limit nearer-term
pipelin asset gener later-stag candid visibl higher includ
bcma antibodi drug conjug multipl myeloma lead way term drug-
base anti-bcma approach car-t bcma novn far behind
phase data gsk drug impress show orr patient tripl refractori
proteasom inhibitors/ immunomodulators/ daratuzumab gsk initi suit pivot trial
monik dream pivot trial line patient triple-refractori began
could conceiv earli path approv given unmet medic need offici guidanc data
impli launch would gsk first meaning cancer medicin almost
exit area us breakthrough therapi design award data
anti-gm-csf ra fulli human antibodi compet crowd ra space
effect associ pain licens morphosi primari endpoint phase trial
statist signific present acr discuss regul advanc phase
ra crowd increasingli gener
daprodustat hif-prolyl hydroxylas inhibitor anemia oral agent meant displac inject
epo/esa product similar azn roxadustat ahead perhap given histori
epo categori regulatori hurdl presum quit high phase trial ascend-d dialysi
readout ascend-n non-dialysi readout began
cabotegravir long-act integras inhibitor hiv treatment possibl prevent
hiv/aid gsk believ patient want everi two-month inject versu daili oral cite
trial proof-of-principl confirmatori trial flair treatment-nav recent toplin posit
potenti launch treatment set differ trial atla treatment-experienc recent
report posit top-line result gsk also pursu prevent high risk individu would
quit novel unclear realist phase trial compar inject cabotegravir
gild truvada at-risk men second phase trial women start potenti launch
prevent like well downstream
fostemsavir attach inhibitor acquisit bmi hiv asset first-in-class drug
treatment-experienc hiv smaller commerci indic phase bright studi recent
page
toplin posit gsk say transfer manufactur delay regulatori submiss
time-frame
growth profil trough return growth thereaft reason
valuat current price-to-earnings multipl lower end full comp sheet see exhibit gsk trade price-to-earnings
multipl ep ep ep use
target price-to-earnings multipl appli ep arriv year end price target
target multipl repres slight contract current price-to-earnings multipl level may occur year
catalyst ep growth neg use price target multipl across cover
compani rang
gsk incom statement revenu forecast balanc sheet/cash flow statement see appendix
financi statement end report
page
merck op pt longer keytruda stori gardasil second major still
compani report factset wolf research price
page
wolf bullet-point view
investor sentiment morph consensu buy last year keytruda almost singular
pipelin prowess late-stag pipelin remain thin histor good core
compet deserv credit nearli flawless execut io continu outpac
binari event risk lower end mostli tie variou io trial readout remain
biggest competitor monitor like stay posit
near-term outlook ep growth look competit bias upsid keytruda grow
faster expect also gardasil under-appreci near- long-term opportun
long-term outlook long-term outlook solidifi nice one stock
coverag capabl post doubl digit ep growth sever driver keytruda gardasil lynparza
possibl lenvima
valuat averag price-to-earnings multipl basi
net becom consensu buy valuat still reason
given above-averag growth profil compar low event risk fulli expect
remain io compani addit driver io upsid form adjuv
trial potenti under-model ex-u io opportun relev
well io compani percept one growth driver keytruda
incorrect view gardasil second major futur growth driver think consensu
under-model tune sever billion dollar written recent furthermor
patent cliff product like meaning competit threat
horizon biggest challeng simpli keep demand also claim
lynparza azn lenvima eisai under-appreci realli need round
stori late-stag pipelin thin moment
ema adopt posit opinion keytruda adjuv therapi melanoma base
eu approv adjuv decemb
report in-lin beat ep guidanc rais also
announc increas dividend share repurchas author includ
fda approv keytruda combin chemotherapi squamou nsclc base
make keytruda first approv set regardless statu
page
fda approv keytruda treatment hepatocellular carcinoma post treatment
sorafenib base
trial investig keytruda mono esophag cancer toplin posit
keytruda improv os compar chemo patient regardless histolog co-primari endpoint
announc acquisit antelliq group subsidiari merck anim
divis euro assum euro debt throw least cold water idea
get rid anim health near-term
fda approv lynparza brcamt advanc ovarian cancer mainten therapi base
result
fda delay sbla target date keytruda monotherapi nsclc three
month april trial widen elig monotherapi popul patient
import upcom event next
keytruda/io indic expans competitor read-out
competitor read-out main threat part look os patient
part chemo combo two cycl chemo opdivo yervoy
earli
ovarian bevacizumab combo regardless brca statu hrrmt mcrpc profound
prevnar follow-on two phase adult trial read pediatr trial read
lenvima tki rcc combo keytruda read-out
page
 would fill pipelin thin context shrink base said
transform deal tabl essenti defin tie-up w/ anoth larg pharma co
impli option tabl could still deal ten billion dollar
three long-term sourc io categori upsid would benefit two market leader
disproportion three long-term sourc import upsid io categori
mind adjuv opportun anti-pdx therapi get use earlier-stag diseas
would translat even bigger difficult quantifi market opportun potenti under-
model ex-u anti-pdx opportun base histor preced meaning cancer drug
usual sell outsid us us consensu current model revers
industri final succeed find synergist agent combin anti-pdx therapi make
greater proport patient respons therapi admittedli lot disappoint
date front
major gardasil upsid substanti under-appreci old vaccin see renew life
move beyond std vaccin prevent hpv cancer vaccin also roll new
geographi china major driver gain broader label higher age rang gender
neutral near monopoli gsk product round error competit en
rout smaller em compani vaccin dont face gener competit think consensu
could underestim sale even beyond last two month
step gardasil estim unabl satisfi demand high-class
problem detail see gardasil major under-appreci growth driver under-model billion
dollar
suddenli one better ep grower doubl digit ep growth averag januvia us
loe single-year blip model
valuat fair rel growth prospect lower event risk
consensu buy keytruda opportun fulli built risk downsid competitor gain
traction opdivo yervoy wolf comment odd posit good data
particular combo low view
io growth driver heavi eros elsewher mrk big base sever franchis
face face commerci pressur either brand loss exclus includ
januvia price risk competit loe start remicad biosimilar zetia/vytorin
loe zostavax gsk wolf comment ignor upsid gardasil/lynparza/lenvima
old use great dead simpli luck bought
sgp similarli sgp luck bought organon wit thin late-stag
page
pipelin despit spend variou setback last mani year apart
keytruda rare use fail trial
outlook biggest market product collect total revenu
keytruda cancer market-lead put pole posit within competit
lucr io market bmi opdivo still viabl alreadi blockbust we/consensu
expect drug doubl size off-pat time-frame
januvia/janumet diabet mrk biggest product keytruda class-lead
inhibitor matur brand face price pressur mount competit oral
therapi sale hold steadi despit
gardasil hpv lead hpv vaccin gsk cervarix nearli round error
futur growth fuel china approv expans older popul also male demand
outstrip suppli work hard increas optim exist footprint
addit new product line
isentress hiv old legaci integras inhibitor ex-growth due competit
newer oral agent pressur gsk off-pat
bridion anesthet surgic anesthesia drug come schering-
plough acquisit seen sharp acceler recent year off-pat
pipelin asset gener later-stag candid visibl higher includ
keytruda approv alreadi variou cancer indic expans true pipelin
drug per se alreadi approv ten tumor type way kidney breast crucial driver
futur compani growth expect high on-going success execut thu far
lynparza parp variou cancer indic expans true pipelin drug per se lynparza
co-develop azn alreadi approv ovarian cancer mani studi
set on-going predict good efficaci variou cancer brca mutat express
infrequ azn/mrk tri expand tumor brca limit combin
therapi exist medicin well pipelin product azn claim commerci
futur compound underestim
page
lenvima multi-kinas inhibitor approv alreadi variou cancer indic expans true
pipelin drug per se new compound came deal eisai easi
overlook given book share revenu net commerci expens allianc
revenu approv thyroid cancer rcc addit on-going combo effort
rcc agreement call combin studi differ tumor type
endometri cancer non-smal cell lung cancer hepatocellular carcinoma head neck cancer bladder
cancer melanoma efficaci compel thu far think investor under-estim
pneumococc conjug vaccin next-gen vaccin evalu adult
pediatr offer two addit serotyp protect pfe class-lead two
phase adult trial read pediatr trial read howev next-gen
vaccin valent also work call question long-term relev mrk product
least adult less year ahead also on-going patent battl
gefapix chronic cough theoret larg patient popul radar
investor seem toler issu dysgeusia recent start highlight
asset frequenc overal pipelin thin concern aris
payer coverag first two chronic cough read
vericiguat sgc partner bayer advanc reduc eject fraction heart failur hfref
despit mix result read-out schedul seem get littl air time
variou earlier-stag io asset either wholly-own partner sting gitr
rig-i cavatak lot support data far compani
growth profil consist solid top- bottom-lin grower
januvia us loe clip growth growth return
page
valuat current price-to-earnings multipl averag full comp sheet see exhibit trade price-to-earnings
multipl ep ep ep use
target price-to-earnings multipl appli ep arriv year end price target target
multipl repres modest expans current price-to-earnings multipl level believ occur
investor come understand under-appreci aspect stori like upsid gardasil
describ report use price target multipl across cover compani rang
mrk incom statement revenu forecast balanc sheet/cash flow statement see appendix
financi statement end report
page
compani report wolf research price
page
wolf bullet-point view novn
investor sentiment slowli turn coincid va take ceo
pipelin prowess abil solid afraid cut edg current late-stag
pipelin full sever compound de-risk
near-term outlook good growth catalyst ahead keep investor engag
long-term outlook reason grower variou creat headwind
net like novarti one easier stori tell full pipelin
compar low risk profil reason growth new ceo va narasimhan execut quarterli
perform sinc take februari investor like one rare ceo hail
 therefor abl talk detail pipelin identifi novarti top pick start
surprisingli favor sentiment steadili warm catalyst ahead
includ continu narrow focu alcon spin-out occasion rumbl get rid
sandoz variou pipelin approvals/launch entresto track well becom mani billion
dollar product investor alway hope jnj eclips trial come gone elimin
overhang long-term growth reason great due variou futur perhap novarti
final becom aggress take cost system way boost ep may mere
pipe dream
report beat ep rais financi guidanc disclos receiv
canakinumab cv risk reduct jeopard futur viabil indic view
fda approv novarti biosimilar humira humira biosimilar approv launch
announc pursu submiss biosimilar rituximab us follow fda request
run new studi novarti say commerci potenti worth late-entr surpris given
novarti histor leader generics/biosimilar recent howev seem
slip regard
host day london major new disclosur rather increment detail
